AbCellera Biologics Inc (NASDAQ:ABCL) shares, rose in value, with the stock price down by -3.31% to the previous day’s close as strong demand from buyers drove the stock to $2.34.
Actively observing the price movement in the recent trading, the stock is buoying the session at $2.42, falling within a range of $2.325 and $2.42. The value of beta (5-year monthly) is 0.452. Referring to stock’s 52-week performance, its high was $4.75, and the low was $2.11. On the whole, ABCL has fluctuated by -19.86% over the past month.
With the market capitalization of AbCellera Biologics Inc currently standing at about $697.29 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 26.29M, with a low estimate of 4.6M and a high estimate of 17M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 7.12M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ABCL’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of ABCL currently trading nearly -2.63% and -18.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.35, while the 7-day volatility ratio is showing 5.68% which for the 30-day chart, stands at 6.86%. Furthermore, AbCellera Biologics Inc (ABCL)’s beta value is 0.45, and its average true range (ATR) is 0.17.
A comparison of AbCellera Biologics Inc (ABCL) with its peers suggests the former has fared considerably weaker in the market. ABCL showed an intraday change of -3.31% in today’s session so far, and over the past year, it shrunk by -48.91%%.
Data on historical trading for AbCellera Biologics Inc (NASDAQ:ABCL) indicates that the trading volumes over the past 10 days have averaged 3.57 and over the past 3 months, they’ve averaged 4.10 million. According to company’s latest data on outstanding shares, there are 295.76 million shares outstanding.
Nearly 24.97% of AbCellera Biologics Inc’s shares belong to company insiders and institutional investors own 37.07% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 22.79 million shares as on 2025-03-14, resulting in a short ratio of 4.6. According to the data, the short interest in AbCellera Biologics Inc (ABCL) stood at 990.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 20.1 million. The stock has fallen by -20.14% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABCL stock heading into the next quarter.
